IJCS | Volume 31, Nº4, July / August 2018

441 Borges et al. Oncocardiology and the symptom fatigue Int J Cardiovasc Sci. 2018;31(4)433-442 Review Article 12. Zwarts MJ, Bleijenberg G, van Engelen BG. Clinical neurophysiology of fatigue. Clin Neurophysiol. 2008;119(1):2-10. 13. Barry BK, Enoka RM. The neurobiology of muscle fatigue: 15 years later. Integr Comp Biol. 2007;47(4):465-73. 14. Saibene F, Minetti AE. Biomechanical and physiological aspects of legged locomotion in humans. Eur J Appl Physiol. 2003;88(4-5):297-316. 15. Powers SK, Howley ET. Fisiologia do exercício. In: Músculo esquelético; estrutura e função. São Paulo: Manole; 2014. 16. Davis MP, Walsh D. Mechanisms of fatigue. J Support Oncol. 2010;8(4):164-74. 17. Ascensão A, Magalhães J, Oliveira J, Duarte J, Soares J. Fisiologia da fadiga muscular. Delimitação conceptual, modelos de estudo e mecanismos de fadiga de origem central e periférica. Revista Portuguesa de Ciências do Desporto. 2003;3(1):108-23. 18. Mckenna MJ, Medved I, Goodman CA, Brown MJ, Bjorksten AR, Murphy KT, et al. N-acetycysteine attenuates the decline inmuscle Na+, K+- pump activity and and delays fatigue during prolonged exercise in humans. J Physiol. 2006;576(Pt 1):279-88. 19. Maughan D, Toth M. Discerning primary and secundary factors responsible for clinical fatigue in multisystem diseases. Biology (Basel). 2014;3(3):606-22. 20. Zambroski CH, Moser DK, Bhat G, Ziegler C. Impact of symptom prevalence and symptom burden on quality of life in patients with heart failure. Eur J Cardiovasc Nurs. 2005;4(3):198-206. 21. Doehmer W, Frenneaux M, Anker SD. Metabolic impairment in heart failure: the myocardic and systemic perspective. J Am Coll Cardiol. 2014;64(13):1388-400. 22. Vescovo G, Dalla Libera L, Serafin F, Leprotti C, Facchin L, Volterrani M, et al. Improved exercise tolerance after Losartan and Enalapril in heart failure: correlation with changes in skeletal muscle myosin heavy chain composition. Circulation. 1998;98(17):1742-9. 23. Dall’ Ago P, Stein R, Ribeiro JP. Exercício empacientes com Insuficiência Cardíaca: do dogma às evidências. Revista da Sociedade de Cardiologia do Rio Grande do Sul. 2005;13(4):1-5. 24. MillerMS, VanBuren P, LeWinterMM, Braddock JM, Ades PA, Maughan DW, et al. Chronic heart failure decreases cross-bridge kinetics in single skeletal muscle fibres from humans. J Physiol. 2010;588(Pt 20):4039-53. 25. Rehn TA, Munkvik, M, Lunde PK, Sjaastad L, Sejersted OM. Intrinsic skeletal muscle alterations in chronic heart failure patients: a disease- specific myopathy or a result of deconditioning? Heart Fail Rev. 2012;17(3):421-36. 26. Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K. The Edmonton SymptomAssssment System (ESAS): a simplemethod for the assessment of palliative care patients. J Palliat Care.1991;7(2):6-9. 27. Ezekowitz JA, Thai V, Hodnefield TS, Sanderson L, Cujec B. The correlation of standard heart failure assessment and palliative care questionnaries in a multidisciplinary heart failure clinic. J Pain Symptom Manage. 2011;42(3):379-87. 28. Servaes P, Verhagen S, Schreuder HW, Veth RP, Bleijenberg G. Fatigue after treatment for malignant and benign bone and soft tissue tumors. J Pain Symptom Manage. 2003;26(6):1113-22. 29. Roberts BM, Ahn B, Smuder AJ, Al-Rajhi M, Gill LC, Beharry AW, et al. Diaphragm and ventilatory dysfunction during cancer cachexia. FASEB J. 2013;27(7):2600-10. 30. Lee JQ, Simmonds MJ, Wang XS, Novy DM. Difference in physical performance between men and women with and without lymphoma. Arch Phys Med Rehabil 2003;84(12):1747-52. 31. Bower JE, Ganz PA, TaoML, HuW, Belin TR, Sepah S, et al. Inflammation biomarkers and fatigue during radiation therapy for breast cancer and prostate cancer. Clin Cancer Res. 2009;15(17):5534-40. 32. Doehner W, von Haehling S, Anker SD, Lainscak M. Neurohormonal activation and inflammation in chronic cardiopulmonary disease: a brief systematic review. Wien Klin Wochenschr. 2009;121(9-10):293-6. 33. Fink MA, Sullivan SL, Zerwic JJ, Piano MR. Fatigue with systolic heart failure. J Cardiovasc Nurs. 2009;24(5):410-7. 34. Escalante CP, Kallen MA, Valdres RU, Morrow PK, Manzullo EF. Outcomes of a cancer-related fatigue clinic in a comprehensive cancer centre. J Pain Simptom Manage. 2010;39(4):691-701. 35. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. May 28, 2009. (4.03: June 14, 2010). Bethesda: U.S. Department of Health and Human Services; National Institutes of Health; National Cancer Institute. 36. Dimeo F, Schwartz S, Wesel N, Voigt A, Thiel E. Effects of an endurance and resistance exercice program on persistent cancer-fatigue after treatment. Ann Oncol. 2008;19(8):1495-9. 37. Schwartz AL, Mori M, Gao R, Nail LM, King ME. Exercise reduces daily fatigue in women with breast cancer receiving chemotherapy. Med Sci Sports Exerc. 2001;33(5):718-23. 38. Mishra SI, Scherer RW, Snyder C, Geigle PM, Berlanstein DR, Topaloglu O. Exercise interventions on health-related quality of life for people with cancer during active treatment. Cochrane Database Syst Rev. 2012 Aug 15;(8):CD008465. 39. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, andmanagement. J AmColl Cardiol. 2009;53(24):2231-47. 40. Adão R, de Keulenaer G, Leite-Moreira A, Brás-Silva C. Cardiotoxicity associated with cancer therapy: pathophysiology and prevention strategies. Rev Port Cardiol. 2013;32(5):395-409. 41. Suter TM, Ewer MS. Cancer drugs and the heart: importance and management. Eur Heart J. 2013;34(15):1102-11. 42. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97(11):2869-79. 43. von Haehling S, Lainscak M, Kung T, Cramer L, Fülster S, Pelzer U, et al. Non-invasive assessment of cardiac hemodynamics in patients with advanced cancer and with chronic heart failure: a pilot feasibility study. Arch Med Sci. 2013;9(2):261-7. 44. Cardinale D, Sandri MT. Role of biomarkers in chemotherapy-induced cardiotoxicity. Prog Cardiovasc Dis. 2010;53(2):121-9. 45. Frickhofen N, Beck FJ, Jung B, Fuhr HG, Andrasch H, Sigmund M. Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil. Ann Oncol. 2002;13(5):797-801. 46. Kosmas C, Kallistratos MS, Kopterides P, Syrios J, Skopelitis H, Mylonaki N, et al. Cardiotoxicity of fluoropyrimidines in different schedulesof administration: a prospective study. J Cancer Res ClinOncol. 2008;134(1):75-82. 47. Moore RA, Adel N, Riedel E, Bhutani M, Feldman DR, Tabbara NE, et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol. 2011;29(25):3466-73. 48. Haugnes HS, Wethal T, Aass N, Dahl O, Klepp O, Langberg CW, et al. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol. 2010;28(30):4649-57. 49. Huddart RA, Norman A, Shahidi M, Horwich A, Coward D, Nicholls J, et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol. 2003;21(8):1513-23. 50. Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007;99(16):1232-9. Erratum in: J Natl Cancer Inst. 2008;100(2):156, J Natl Cancer Inst. 2008;100(9):685.